Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Neoplasms 1 Melanoma 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 36 Nivolumab 32 Bevacizumab 13 Sunitinib 10 Ipilimumab 10 aldesleukin 7 Interleukin-2 7 Axitinib 7 lenvatinib 6 cabozantinib 6 Paclitaxel 6 Everolimus 6 Docetaxel 6 Cyclosporine 6 Cyclophosphamide 6 fludarabine phosphate 5 Sorafenib 5 Radiotherapy 5 Peripheral Blood Stem Cell Transplantation 5 Mycophenolic Acid 5 fludarabine 4 cemiplimab 4 belzutifan 4 Whole-Body Irradiation 4 Radiosurgery 4 Interferon-alpha 4 Cetuximab 4 durvalumab 3 bempegaldesleukin 3 avelumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Carcinoma, Renal Cell × Protein Subunit Vaccines × Clear all

NCT02429440 2017-08-17

UroRCC

University Hospital Tuebingen

Phase 1/2 Unknown

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡